FDA Alerts
FDA Approves Xeljanz For Rheumatoid Arthritis
The US Food and Drug Administration approved Xeljanz ( tofacitinib ) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate .
FDA Recommends Approval of Tofacitinib
Pfizer Inc. announced that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
New Drug for Rare Childhood Arthritis
The FDA has a approved a new drug to treat systemic juvenile idiopathic arthritis - a rare type of arthritis but the most common form affecting children.